Hertz, Daniel L.
Douglas, Julie A.
Miller, Robert M.
Kidwell, Kelley M.
Gersch, Christina L.
Desta, Zeruesenay
Storniolo, Anna Maria
Stearns, Vered
Skaar, Todd C.
Hayes, Daniel F.
Henry, N. Lynn
Rae, James M.
Funding for this research was provided by:
National Institute of General Medical Sciences (U-01 GM61373, 5T32-GM08425, GM099143)
National Center for Research Resources (M01-RR000042, M01-RR00750, M01-RR00052)
Breast Cancer Research Foundation (N003173)
National Cancer Institute (5T32CA083654, P30 CA046592)
Article History
Received: 2 February 2022
Accepted: 20 June 2022
First Online: 1 July 2022
Declarations
:
: This was a retrospective secondary analysis of a previously reported prospective clinical study. The prospective study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of each of the three participating Universities.
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent to participate. No individual data was included in this manuscript.
: This work was supported in part by Pfizer and Novartis Pharma AG. Dr. Stearns has received research funding from Abbvie, Biocept, Celgene, Merck, Novartis, Medimmune, Pfizer, and Puma Biotechnology. Dr. Stearns is on an advisory board for Novartis (10/25/2021, is a member of the Data Safety Monitoring Board for Immunomedics, Inc, and Chair of the Data Safety Monitoring Board for AstraZeneca, and has received non-financial support from Foundation Medicine Study Assays. Dr. Henry has received research funding to conduct pharmaceutical sponsored clinical trials from Abbvie, Innocrin Pharmaceuticals, Pfizer, and Blue Note Therapeutics. Dr. Hayes reports research funding from Merrimack Pharmaceuticals, Eli Lilly, Menarini Silicon Biosystems, Puma Biotechnology, Pfizer, and Astra Zeneca in the last 24 months. He also reports consulting fees from Cepheid, Freenome, Artiman Ventures, Agendia, Lexent Bio, Epic Sciences, and Salutogenic Innovations. He is the named investigator of a patent held by the University of Michigan which is licensed to Menarini Silicon Biosystems, from whom he receives annual royalties. He holds stock options in Oncimmune LLC and InBiomotion.